left-arrow right-arrow pinterest facebook google_plus linkedin

Skin Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


ARRAY-818-103

Status: Recruiting | Phase I

Official Title: A Sequential 2-Arm, Open-Label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

Study Purpose: The main purpose of the ARRAY-818-103 study is to look at the effect of encorafenib and binimetinib (the study drugs) on the activity of other common drugs.  The study will also look at safety and how participants tolerate the study drugs when given with the other common drugs. Learn more


ECOG-ACRIN EA6134

Status: Recruiting | Phase III

Original Title: Testing Therapy Sequence for Advanced BRAF Mutation Melanoma

Study Purpose: The purpose of this study to compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when it gets worse. Learn more


ECOG-ACRIN EA6141

Status: Suspended | Phase II/III 

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma.

Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together. Learn more


ECOG-ACRIN EA6174

Status: Recruiting | Phase III

Official Title: Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery

Study Purpose: This study is being done to see if the chance of cancer growing back can be lowered by adding the study drug, pembrolizumab, after surgery. Learn more.


SWOG S1616

Status: Recruiting | Phase II

Official Title: Testing treatment with Ipilimumab and Nivolumab compared to treatment with Ipilimumab alone in advanced melanoma.  

Study Purpose: The purpose of this study is to compare any good and bad effects of using Ipilimumab in combination with Nivolumab to the usual approach of treating with Ipilimumab alone. Learn more


SWOG S1801

Status: Recruiting | Phase II

Official Title: A phase II randomized study of adjuvant vs. neoadjuvant MK-3475 (Pembrolizumab) for clinically detectable stage III-IV high-risk melanoma.

Study Purpose: The purpose of this study is to compare outcomes of receiving the study drug either before and after or only after surgery for your type of cancer. Learn more